The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2020 | Evidence for local treatment of oligometastatic disease
Dirk De Ruysscher, MD, PhD, Maastricht University Medical Center, Maastricht, Netherlands discusses the evidence for local treatment of oligometastatic lung cancer as presented at the ESMO 2020 education weekend. Dr De Ruysscher summarizes findings from key trials emphasizing the improvements in progression-free survival and overall survival seen in patients with synchronous oligometastatic disease and patients with metachronous oligometastatic disease when local treatment is combined with systemic treatment. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
